Budesonide MMX® is a corticosteroid inserted in a MMX® technology formulation that acts as an anti-inflammatory drug. It is the active ingredient in a number of treatments for asthma, non-infectious rhinitis (including hay fever and other allergies), nasal polyposis and Crohn’s Disease. Budesonide MMX® is currently being clinically developed by Cosmo and Phase III clinical trials are currently being designed.

Budesonide MMX® is an oral tablet formulation which delivers Budesonide directly to the lumen of the colon. The specific drug dissolution profile increases the colonic specific bio-availability of Budesonide and reduces the pre-colonic systemic absorption. The intended reduction of systemic absorption reduces side effects associated with drug treatment while the intended delivery to the colon enables the product to be especially effective in the treatment of proximal and distal Ulcerative Colitis. Phase II clinicals trials are underway in the USA and EU; Enrolment was completed

Cosmo’s patent expires in the year 2020.



Back to top